Moderna’s COVID-19 Vaccine Spikevax Receives Full FDA Approval for Children Aged 6 Months to 11 Years at “Increased Risk”

by Jim Hᴏft, TGP The U.S. Food and Drug Administration (FDA) has officially granted full approval to Moderna’s controversial mRNA COVID-19 vaccine, Spikevax, for children as young as 6 months old…[...]

Read More

Anxiety and Depression-Related Factors in Hospitalized Patients Diagnosed With Coronavirus Disease 2019: A Detailed Cross-Sectional Analysis From a Tertiary Center

Arzu Kaplanoglu • Arzu Sonmez • Oznur Yildirim • et. al.,DOI: 10.7759/cureus.77865  Abstract Aim During pandemic periods, psychogenic assessment and precautions are critical for patients requiring hospitalization. This study investigates the factors influencing anxiety levels in patients…[...]

Read More

Immunological and Antigenic Signatures Associated with Chronic Illnesses after COVID-19 Vaccination

Bornali Bhattacharjee, Peiwen Lu, Valter Silva Monteiro, et. al. doi: https://doi.org/10.1101/2025.02.18.25322379 Yale Study Reveals Shocking Truth: Spike Protein Lingers – and Grows SUMMARY COVID-19 vaccines have prevented millions of COVID-19 deaths. Yet, a small fraction of the…[...]

Read More

FDA scrutiny of Novavax COVID-19 vaccine sparks uncertainty about other shots

By  LAURAN NEERGAARD and MATTHEW PERRONE WASHINGTON (AP) — The Trump administration’s effort to impose new requirements on Novavax’s COVID-19 vaccine — the nation’s only traditional protein-based option for the coronavirus — is sowing uncertainty about updates to other…[...]

Read More

Post-inflammatory Pigmentary Alteration (PIPA)-Like Disorder Following COVID-19 Vaccination

Larry M. Bush • Priscila M. Fiallo • Maria T. Vazquez-Pertejo, DOI: 10.7759/cureus.87222  Abstract SARS-CoV-2 (COVID-19) infection has been associated with various cutaneous manifestations presenting concomitantly with and following clinical resolution of active infection. Similarly,…[...]

Read More